MedTrace Logo

Study of the Safety, Tolerability, Pharmacokinetics of VV261 Tablets in Chinese Healthy Volunteers

NCT07302269 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2026-03-03

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics characteristics of VV261 tablets in healthy adults.

Conditions

  • Healthy Volunteers

Interventions

DRUG

VV261 5mg group

2 subjects will receive VV261 5mg, orally

DRUG

VV261 20mg Group

6 subjects receive VV261 20mg,orally; 2 subjects will receive placebo,orally.

DRUG

VV261 50mg group

6 subjects receive VV261 50mg,orally; 2 subjects will receive placebo,orally.

DRUG

VV261 100mg group

6 subjects receive VV261 100mg,orally; 2 subjects will receive placebo,orally.

DRUG

VV261 150mg group

6 subjects receive VV261 150mg,orally; 2 subjects will receive placebo,orally.

DRUG

VV261 300mg group

6 subjects receive VV261 300mg,orally; 2 subjects will receive placebo,orally.

DRUG

VV261 500mg group

6 subjects receive VV261 500mg,orally; 2 subjects will receive placebo,orally.

DRUG

VV261 750mg group

6 subjects receive VV261 750mg,orally; 2 subjects will receive placebo,orally.

DRUG

VV261 1000mg group

6 subjects receive VV261 1000mg,orally; 2 subjects will receive placebo,orally.

Sponsors & Collaborators

  • Vigonvita Life Sciences

    lead INDUSTRY

Principal Investigators

  • Huan Zhou · The First Affiliated Hospital of Anhui Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-04
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07302269 on ClinicalTrials.gov